Teva cuts guidance yet again as Copaxone copies, generics pressure take their toll
admin 2nd November 2017 Uncategorised 0On a day that Teva chairman Sol Barer described as “the beginning of the next chapter for our company,” all analysts got was more of the same. For the third time in the last four quarters, the company slashed its guidance, bringing its expected revenue range down to $22.2 billion to $22.3 billion.
More: Teva cuts guidance yet again as Copaxone copies, generics pressure take their toll
Source: fierce